OwlyTimes
James Chen

James Chen

James Chen — Editor-in-Chief at OwlyTimes, which he founded in 2025 with a small team of editors. Reports on markets with a CPA's suspicion and a reporter's notebook. Came to the project after seven years on a regional business desk in Chicago, where he learned to read footnotes before press releases. Numbers tell stories; he edits the stories so they tell the truth.

1488 articles published

Latest Articles

Ozempic & Wegovy Price Cuts: A Strategic Shift AnalyzedBusiness

Ozempic & Wegovy Price Cuts: A Strategic Shift Analyzed

Uncover the *real* reason behind Novo Nordisk’s Ozempic & Wegovy price cuts. Our analysis reveals a strategic shift reshaping GLP-1 access—beyond the headlines.

Chime's $596M Surge: Impact on the Underbanked MarketBusiness

Chime's $596M Surge: Impact on the Underbanked Market

Decode Chime's $596M revenue surge! We analyze what this fintech giant's growth reveals about the underbanked market and its future. Gain key insights now.

NJBAC Surge: What 47K Inquiries Signal for BusinessesBusiness

NJBAC Surge: What 47K Inquiries Signal for Businesses

Uncover why NJ businesses flooded the NJBAC with 47K inquiries in 2025. Our analysis reveals a concerning shift: reactive problem-solving over proactive growth.

Biotech Boost: HBS Dual Degree's $80K ImpactBusiness

Biotech Boost: HBS Dual Degree's $80K Impact

Uncover the strategy behind HBS's lucrative biotech program! We analyze how this $80K premium reveals a shift towards leaders bridging science & business.

Avalon GloboCare: $3.25M Raise Signals AI Pivot & Survival StakesBusiness

Avalon GloboCare: $3.25M Raise Signals AI Pivot & Survival Stakes

Uncover the hidden story behind Avalon GloboCare's $3.25M raise. We analyze if this AI pivot is a lifeline or a last-ditch effort for survival.

Ozempic's Impact: How Puris Proteins Built a $200M EmpireBusiness

Ozempic's Impact: How Puris Proteins Built a $200M Empire

Uncover the surprising link between Ozempic & pea protein! See how Puris Proteins built a $200M empire by anticipating the 'Ozempic generation's' needs.

Micron's 326% Surge: AI Signal or Silicon Bubble?Finance

Micron's 326% Surge: AI Signal or Silicon Bubble?

Uncover the truth behind Micron's explosive 326% surge! Is it a genuine AI play or a silicon bubble? Our analysis reveals the critical infrastructure fueli...

Paramount-Skydance Deal: A Streaming Shift & What It SignalsBusiness

Paramount-Skydance Deal: A Streaming Shift & What It Signals

Uncover the surprising Paramount-Skydance deal's deeper meaning! We analyze what this Netflix loss signals for streaming's future & independent content's s...

Dorsey's Block: Generous Severance Signals a Shift in Tech LayoffsBusiness

Dorsey's Block: Generous Severance Signals a Shift in Tech Layoffs

Uncover why Block's generous severance packages defy tech layoff trends. Our analysis reveals a strategic bet on morale & future innovation—follow the money!

Thames Water Fine: A Signal of Systemic Sewage Failure?Business

Thames Water Fine: A Signal of Systemic Sewage Failure?

Uncover the truth behind Thames Water's record fine. Is it a deterrent or just a cost of doing business? Analyze the systemic sewage crisis & follow the money.

Luotea Plc: Profit Surge Signals a Major Shift After DemergerBusiness

Luotea Plc: Profit Surge Signals a Major Shift After Demerger

Uncover the hidden story behind Luotea's profit surge! Our analysis reveals how a recent demerger is reshaping the company, redefining its strategy, and im...

Caesars' 19% Jump: A Takeover Signal? Analysis.Business

Caesars' 19% Jump: A Takeover Signal? Analysis.

Uncover the hidden forces behind Caesars' surprising stock jump! Our analysis reveals if a takeover is brewing & what it means for the casino industry's future.